益赛普联合沙利度胺治疗难治性强直性脊柱炎临床研究

摘要

Objective To investigate the clinical efficacy of Thalidomide combined with Etanercept for treating refractory ankylosing spondylitis. Methods Totally 80 cases of refractory ankylosing spondylitis patients in our hospital were selected and randomly divided into the control group and the observation group. 40 cases in each group. The control group was treated with Thalidomide. the observa-tion group was treated with Thalidomide combined with Etanercept. The BASFI. morning stiffness time. ESR. CRP and other indicators were observed. the clinical efficacy and adverse reaction monitoring were compared between the two groups. Results After treatment. the time of morning stiffness. joint pain. number of pillow wall distance. BASFI in the observation group were significantly lower than those in the control group. but the thorax expansion in the observation group was significantly higher than that in the control group ( P 0. 05 ) . Conclusion Thalidomide combined with Etanercept for treating refractory ankylosing spondylitis has reliable effect. and can effectively improve the clinical symptoms. the clinical application is safe and effective.%目的 探讨益赛普联合沙利度胺治疗难治性强直性脊柱炎的临床疗效.方法 将医院收治的难治性强直性脊柱炎患者80例随机分为对照组和观察组,各40例.对照组采用沙利度胺治疗,观察组采用益赛普联合沙利度胺治疗,观察两组患者Bath强直性脊柱炎功能指数(BASFI)、晨僵时间、红细胞沉降率(ESR)和C反应蛋白(CRP)等指标变化,比较两组临床疗效,并监测不良反应.结果 治疗后,观察组晨僵时间、关节疼痛个数、枕壁距、BASFI指标显著低于对照组,胸廓扩张度显著高于对照组,组间差异均显著(P0.05).结论 沙利度胺联合益赛普治疗难治性强直性脊柱炎疗效可靠,可有效改善患者的临床症状,且临床应用安全.